Because the increase in caspase-3 activity has been proposed as an early neurodegenerative event in AD progression [34-36], its quantification might be useful in evaluating the efficacy of neuroprotective pharmacological treatment. The gene discussed is CASP3; the disease is Alzheimer disease.